Insulet Corporation logo

Insulet Corporation (GOV)

Market Open
5 Dec, 15:01
267. 10
+4.1
+1.56%
- Market Cap
56.74 P/E Ratio
0% Div Yield
0 Volume
2.99 Eps
263
Previous Close
Day Range
267.1 269.4
Year Range
204.9 302.4
Want to track GOV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 76 days

Summary

GOV trading today higher at €267.1, an increase of 1.56% from yesterday's close, completing a monthly decrease of -3.61% or €10. Over the past 12 months, GOV stock gained 6.67%.
GOV is not paying dividends to its shareholders.
The last earnings report, released on Nov 06, 2025, exceeded the consensus estimates by 0.1%. On average, the company has fell short of earnings expectations by -0.26%, based on the last three reports. The next scheduled earnings report is due on Feb 19, 2026.
The stock of the company had never split.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

GOV Chart

Here's Why Insulet (PODD) is a Strong Growth Stock

Here's Why Insulet (PODD) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 day ago
Artisan International Small-Mid Fund Q3 2025 Contrarianism Pays Off

Artisan International Small-Mid Fund Q3 2025 Contrarianism Pays Off

Our philosophy often runs counter to prevailing market sentiment, especially in times of excessive concentration and narrow market leadership. During this time, when many investors saw insulin pumps as “GLP-1 losers,” we acquired a position in Insulet (PODD) and added to our position in ConvaTec (CNVVY). We acquired shares of SolarEdge on the day the Trump administration began to review the Biden agenda.

Seekingalpha | 1 week ago
Looking for a Growth Stock? 3 Reasons Why Insulet (PODD) is a Solid Choice

Looking for a Growth Stock? 3 Reasons Why Insulet (PODD) is a Solid Choice

Insulet (PODD) could produce exceptional returns because of its solid growth attributes.

Zacks | 1 week ago

Insulet Corporation (GOV) FAQ

What is the stock price today?

The current price is €267.10.

On which exchange is it traded?

Insulet Corporation is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is GOV.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 1.46.

When is the next earnings date?

The next earnings report will release on Feb 19, 2026.

Has Insulet Corporation ever had a stock split?

No, there has never been a stock split.

Insulet Corporation Profile

- Industry
- Sector
Ashley A. McEvoy CEO
XDUS Exchange
US45784P1012 ISIN
US Country
3,900 Employees
- Last Dividend
- Last Split
15 May 2007 IPO Date

Overview

Insulet Corporation is a pioneering healthcare company that specializes in the development, manufacturing, and sale of innovative insulin delivery systems intended primarily for individuals with insulin-dependent diabetes. Founded in the year 2000 and with its headquarters located in Acton, Massachusetts, Insulet Corporation aims to improve the quality of life for people living with diabetes through its cutting-edge products. The company markets its solutions across a broad geographic spectrum including the United States, Canada, Europe, the Middle East, Australia, and other international markets, leveraging both direct sales and a network of independent distributors and pharmacy channels.

Products and Services

  • Omnipod 5 Automated Insulin Delivery System (Omnipod 5)

The Omnipod 5 stands out as a flagship offering from Insulet Corporation, showcasing a proprietary Automated Insulin Delivery (AID) algorithm built into the Pod. This system is designed to seamlessly integrate with a third-party continuous glucose monitor (CGM), with the aim of obtaining glucose readings via wireless Bluetooth communication. This integration facilitates a dynamic adjustment of insulin delivery, aiming to maintain glucose levels within the target range, hence offering a sophisticated solution to insulin management.

  • Omnipod DASH

Omnipod DASH elevates the convenience of insulin delivery systems by featuring a Bluetooth-enabled Pod, which is managed through a user-friendly Personal Diabetes Manager (PDM). The PDM, resembling a smartphone in its design, comes equipped with a color touch screen user interface. This system provides users a blend of advanced technology and ease of use, making daily diabetes management more manageable and less intrusive.

  • Omnipod GO

The Omnipod GO system introduces a standalone, wearable insulin delivery solution that administers a fixed rate of continuous rapid-acting insulin over a duration of 72 hours. This system is tailored for those seeking simplicity and effectiveness in their insulin therapy, catering especially to individuals who prefer a straightforward approach to diabetes management without the need for frequent adjustments.

Contact Information

Address: 100 Nagog Park
Phone: 978 600 7000